IBS Patient Community - IBSpatient.org - IBS News
Updated: 1 hour 4 min ago
Independent.ie Gut instinct Independent.ie The researchers concluded that "the multi-strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients, and was well tolerated. These results suggest this probiotic confers benefit in IBS ... View the full article
Pubmed-Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease.
Related Articles Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. Am J Gastroenterol. 2018 Feb 16;: Authors: Gracie DJ, Hamlin PJ, Ford AC Abstract OBJECTIVES: The impact of irritable bowel syndrome (IBS)-type symptoms on the natural history of inflammatory bowel disease (IBD) is uncertain. We aimed to address this in a longitudinal study of secondary care patients. METHODS: Longitudinal disease activity was defined by disease flare, escalation of medical therapy, hospitalization, or intestinal resection. The number of investigations performed and clinics attended determined healthcare utilization. Psychological well-being and quality of life were assessed using validated questionnaires. These outcomes were compared over a minimum period of 2 years between patients reporting IBS-type symptoms and patients with quiescent disease, occult inflammation, and active disease at baseline. RESULTS: In 360 IBD patients, there were no differences in longitudinal disease activity between patients with IBS-type symptoms and patients with quiescent disease or occult inflammation. Disease flare and escalation of medical therapy was more common in patients with active disease than in patients with IBS-type symptoms (hazard ratio (HR) = 3.16; 95% confidence interval (CI) 1.93-5.19 and HR = 3.24; 95% CI 1.98-5.31, respectively). A greater number of investigations were performed in patients with IBS-type symptoms than quiescent disease (P = 0.008), but not compared with patients with occult inflammation or active disease. Anxiety, depression, and somatization scores at follow up were higher, and quality-of-life scores lower, in patients with IBS-type symptoms when compared with patients with quiescent disease, but were similar to patients with active disease. CONCLUSIONS: IBS-type symptoms in IBD were associated with increased healthcare utilization, psychological comorbidity, reduced quality of life, but not adverse disease activity outcomes during extended follow-up. PMID: 29453384 [PubMed - as supplied by publisher] View the full article
Futurism “Intestine-Chip” Could Help Patients With Diseases Like Crohn's Futurism Patients with debilitating gastrointestinal diseases like Crohn's disease, ulcerative colitis, and irritable bowel syndrome often have to try several costly treatments before they find one that works for them. These drugs can cause individuals painful ... Scientists from Cedars-Sinai and Emulate Produce Human Intestinal ...Business Wire (press release) Scientists produce human intestinal lining that re-creates living tissue inside organ-chipEurekAlert (press release) Scientists produce human intestinal lining that re-creates living ...Medical Xpress Chicago Evening Post all 3 news articles » View the full article
Niki Bezzant: Learning to control gut instinct New Zealand Herald Fodmaps — it's possibly the least catchy acronym in the world (made up from an even less catchy list of classic irritant food types), but it's a very important one for anyone who struggles with bloating, pain and other symptoms associated with ... View the full article
Pubmed-Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells.
Related Articles Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells. Saudi J Gastroenterol. 2018 Jan-Feb;24(1):59-66 Authors: Cao YN, Feng LJ, Wang BM, Jiang K, Li S, Xu X, Wang WQ, Zhao JW, Wang YM Abstract Background/Aims: Probiotics play a role in relieving irritable bowel syndrome (IBS); however, the underlying mechanism is yet unclear. The aim of the study was to investigate the effects of the supernatants of Lactobacillus acidophilus and Bifidobacterium longum on the expression of serotonin transporter (SERT) messenger ribonucleic acid (mRNA) and protein. Materials and Methods: HT-29 and Caco-2 cells were treated with different concentrations of L. acidophilus and B. longum supernatants for 12 h and 24 h, respectively. SERT mRNA and proteins levels were detected by real-time polymerase chain reaction (real-time PCR) and Western-blotting. Results: The mRNA levels of SERT in HT-29 and Caco-2 cells treated with different concentrations of L. acidophilus or B. longum supernatants for 12 h and 24 h, each, were higher than that in the control groups. In addition, the expression of the protein in both cells was also upregulated, which was approximately similar to that of the corresponding mRNA. Conclusions: L. acidophilus and B. longum supernatants can upregulate SERT mRNA and protein levels in intestinal epithelial cells. PMID: 29451186 [PubMed - in process] View the full article
Pubmed-The prevalence of celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome of China, a prospective, controlled, cohort study.
Related Articles The prevalence of celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome of China, a prospective, controlled, cohort study. J Dig Dis. 2018 Feb 16;: Authors: Kou G, Guo J, Zuo X, Li C, Liu C, Ji R, Liu H, Wang X, Li Y Abstract BACKGROUND: Celiac disease (CD) is a chronic inflammatory enteropathy with a symptom spectrum similar to that of irritable bowel syndrome (IBS). CD is a common, but largely undiagnosed, condition in Western countries. However, it is extremely rare among Chinese people, and few studies have evaluated its prevalence in China. OBJECTIVE: To determine the prevalence of CD in IBS patients diagnosed using the Rome III criteria in North China. METHODS: This was a single-center, prospective, controlled cohort study performed in Qilu Hospital involving 246 IBS patients and 246 healthy controls. Blood samples were drawn for assessment of serum tTg-IgA. Patients with a positive tTg-IgA test result were subjected to probe-based confocal laser endomicroscopy (pCLE) and duodenal biopsy to confirm CD. RESULTS: Twelve patients with IBS (4.84%) and two healthy controls (0.81%) were positive for serum tTG-IgA. Of them, five IBS patients underwent pCLE and targeted biopsy; all were confirmed to have CD. After implementation of a gluten-free diet, seven serologically positive IBS patients showed clinical improvement, for a minimum prevalence of CD among IBS patients of 2.85%. CONCLUSION: CD is not rare in Chinese people, particularly among those with IBS. Therefore, CD should receive greater attention in clinical practice in China. PMID: 29451364 [PubMed - as supplied by publisher] View the full article
Related Articles Advancements in drug development for diarrhea-predominant irritable bowel syndrome. Expert Opin Investig Drugs. 2018 Feb 16;: Authors: Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F Abstract Introduction Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common disorder characterized by a complex pathophysiology hampering optimal targeted drug development. Recent advances in our understanding of key underlying mechanisms prompted novel therapeutics including novel pharmacological approaches. Areas covered This review summarizes the latest advancements in the pipeline of IBS-D drugs focusing on new pharmacological targets, efficacy and safety of medicinal products considering the recent harmonization of regulatory requirements by the FDA and the EMA. Expert opinion The new 5-HT3 receptor antagonist ramosetron appears a promising therapeutic approach devoid of significant adverse events, although it is presently unavailable in Western countries, most likely because of the precautionary approach taken by regulatory agencies with this drug class. New pharmacological concepts on full agonists/antagonists, mixed-receptor activity and novel drug targets may streamline the present drug pipeline along with the adherence on new regulatory guidelines on outcome measures. Eluxadoline can be taken as an example of this paradigm shift. It has now been granted marketing authorization for IBS-D on both sides of the Atlantic, but it is still considered as a second-line agent by the NICE. There is still much work to be done to fully cover clinical needs of patients with IBS-D. PMID: 29451407 [PubMed - as supplied by publisher] View the full article
Google-This Physician Scientist's Food Startup Targets People With Digestive Issues - Black Enterprise
Black Enterprise This Physician Scientist's Food Startup Targets People With Digestive Issues Black Enterprise A lot of Americans have complained about digestive troubles at one time or another. Irritable Bowel Syndrome, or IBS as its commonly known, is different though. For people suffering from IBS, sometimes it is almost impossible to eat a meal. Symptoms ... View the full article
A look at different types of poop, which has a range of consistencies and odors. Learn more about the different types and what they mean here. View the full article
Pubmed-The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2018 Feb 14;8(1):2964 Authors: Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ Abstract Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum (CB) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of CB in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundred patients with IBS-D were recruited and were given CB or placebo for 4 weeks. End points included change from baseline in IBS symptoms, quality of life, stool consistency and frequency. Compared with placebo, CB is effective in improving the overall IBS-D symptoms (-62.12 ± 74.00 vs. -40.74 ± 63.67, P = 0.038) as well as quality of life (7.232 ± 14.06 vs. 3.159 ± 11.73, P = 0.032) and stool frequency (-1.602 ± 1.416 vs. -1.086 ± 1.644, P = 0.035). The responder rates are found higher in CB compared with the placebo (44.76% vs. 30.53%, P = 0.042). The change in fecal microbiota was analyzed and function pathways of CB in treating IBS-D were predicted. In conclusion, CB improves overall symptoms, quality of life and stool frequency in IBS-D patients and is considered to be used as a probiotics in treating IBS-D clinically. PMID: 29445178 [PubMed - in process] View the full article
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2018 Feb 15;9(2):e134 Authors: Stern EK, Brenner DM Abstract Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of IBS by altering gastrointestinal homeostasis. Therapeutic interventions for IBS with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification. SYN-010 is a modified-release statin formulation that reduces methane production by Methanobrevibacter smithii and is currently in development for the treatment of patients with constipation-predominant IBS. Use of these interventions in the management of patients with IBS may function to restore a healthy gut microbiota and ameliorate symptoms of IBS. PMID: 29446765 [PubMed] View the full article
Pubmed-The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome.
The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome. J Ment Health. 2018 Feb 15;:1-3 Authors: Windgassen S, Moss-Morris R, Goldsmith K, Chalder T PMID: 29447026 [PubMed - as supplied by publisher] View the full article
Pubmed-Small Fiber Polyneuropathy Is Prevalent in Patients Experiencing Complex Chronic Pelvic Pain.
Small Fiber Polyneuropathy Is Prevalent in Patients Experiencing Complex Chronic Pelvic Pain. Pain Med. 2018 Feb 13;: Authors: Chen A, De E, Argoff C Abstract Objective: To demonstrate the prevalence of small fiber polyneuropathy (SFPN) in patients with refractory chronic pelvic pain (CPP). Design: Retrospective study of prospective database. Subjects: Participants were complex CPP patients recruited from subspecity referral clinics defined as those who were refractory to initial treatment and/or exhibited comorbid pain syndromes at initial presentation. Methods: Comprehensive treatment history for CPP was obtained, and participants referred as above; 3-mm punch biopsies were obtained of the lower extremity and sent to diagnostic reference labs to evaluate for SFPN. The reported lab sensitivity and specificity for SFPN are 78-92% and 65-90%, respectively. Results: Twenty-five of 39 patients (64%) were positive for SFPN. Comorbid conditions noted in our population included gastroesophageal reflux disease (46%), migraine (38%), irritable bowel syndrome (33%), lower back pain (33%), fibromyalgia (38%), endometriosis (15%), interstitial cystitis (18%), vulvodynia (5%), and other chronic pain syndromes (36%). Conclusions: The prevalence of SFPN in our specialty referral patients with complex CPP is remarkably high vs published general population prevalence data (53/100,000). Identification of SFPN in this complex population shifts the focus from undefined syndromes to symptom complexes with linked potentially treatable mechanisms (e.g., SFPN, central sensitization). Most CPP patients with SFPN are undiagnosed. Considering the diagnosis may expand treatment options beyond conventional or so-called adjuvant analgesics. Treatment may expand to therapies such as IV lidocaine, IVIG, or other immunomodulatory options. In addition, the value to the patient of receiving a diagnosis for a multisystem or refractory pain syndrome, often attributed to negative psychologic factors, cannot be underestimated. Identifying SFPN should be contemplated in CPP patients who present with multisystem pain or who have not responded to initial evaluation and management. PMID: 29447372 [PubMed - as supplied by publisher] View the full article
Times Lifestyle Best Probiotic for Irritable Bowel Syndrome Times Lifestyle From a recent study, it has been identified that around 15% of the world population is suffering from irritable bowel syndrome. If you too are affected with it, you will have to experience irregular bowl habits. This will be dominated by constipation ... View the full article
Women's Health 9 IBS Treatments That Will Free You From The Toilet Seat Women's Health Created by Monash University in Australia, the low FODMAP diet is designed to treat IBS symptoms. FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (phew!), which are short-chain carbs that aren't properly ... View the full article
Pubmed-DSP-6952, a novel 5-HT4 receptor partial agonist, inhibits visceral hypersensitivity and ameliorates gastrointestinal dysfunction in experimental animals.
DSP-6952, a novel 5-HT4 receptor partial agonist, inhibits visceral hypersensitivity and ameliorates gastrointestinal dysfunction in experimental animals. Eur J Pharmacol. 2018 Feb 08;: Authors: Mine Y, Itakura T, Oku S, Asada R, Shimizu I Abstract The pharmacological profile of DSP-6952, a novel 5-HT4 receptor partial agonist, was investigated to evaluate the potential use for GI disorders, and to compare its effects in some GI dysfunction models with those of clinically efficacious prokinetic agents. DSP-6952 enhanced gastric motility and caused colonic giant migrating contractions (GMCs) associated with defecation in conscious dogs, having ED50 value for inducing GMCs of 1.56mg/kg. DSP-6952 (3-10mg/kg, i.g.) significantly enhanced colonic transit rate in guinea pigs; this enhancement was antagonized by SB-207266, a selective 5-HT4 receptor antagonist. DSP-6952 (1-10mg/kg, p.o.) rapidly increased fecal wet weight without increasing fluid content in mice. Sennoside (30-100mg/kg, p.o.) also increased fecal wet weight; however, it significantly increased fluid content with diarrhea. DSP-6952 dose-dependently improved clonidine- and morphine-induced delay in whole-gut transit in mice (ED50 = 0.429mg/kg and 0.310mg/kg, respectively), which represented atonic and spastic constipation models, respectively. In viscerally hypersensitive rats treated with acetic acid, DSP-6952 (10mg/kg, i.p., 30mg/kg, p.o., 30mg/kg, i.c.) and tegaserod (1mg/kg, i.p.), but not prucalopride (10mg/kg, i.p.), significantly inhibited the increase in colorectal distension-induced visceromotor response; these findings suggest that DSP-6952 and tegaserod inhibit visceral hypersensitivity in rats. It was concluded that DSP-6952, a novel and orally available 5-HT4 receptor agonist, induced colonic GMCs, enhanced colonic transit, increased defecation without inducing diarrhea, improved drug-induced delay in whole-gut transit, and inhibited visceral hypersensitivity in experimental animals. Therefore, DSP-6952 is expected to become a useful drug for treatment of IBS-C and chronic constipation. PMID: 29428470 [PubMed - as supplied by publisher] View the full article
Learn about why your stomach feels tight. We take a look at the various causes, treatments, and conditions associated with a tight stomach. View the full article
MedPage Today Opioid Receptor Antagonists Safe for Opioid-Induced Constipation MedPage Today And while the number needed to treat was consistent with results from studies of treatment for functional constipation or irritable bowel syndrome (IBS) with constipation, there may be other patients who get a partial response, Grover said. The meta ... and more » View the full article
Google-Arthritis or IBS symptoms? Adding a pinch of this spice to your tea can help relieve pain - Express.co.uk
Express.co.uk Arthritis or IBS symptoms? Adding a pinch of this spice to your tea can help relieve pain Express.co.uk Health benefits. The health food shop says among its benefits it has anti-inflammatory, anti-oxidant and wound-healing properties. It is as effective as some anti-inflammatory drugs for people who suffer from IBS (irritable bowel syndrome), Crohn's ... View the full article
Globalnews.ca 8 types of food to avoid if you have irritable bowel syndrome Globalnews.ca And food, De Santis says, is often a trigger of these symptoms. “Understanding the foods that cause or worsen symptoms, and controlling the amount of those foods that one consumes, can make a massive difference for many people,” De Santis says. “For ... View the full article